With Proxy Fight Averted, Genzyme Can Review Damage Done By A Year Of Manufacturing Troubles
Now that Genzyme has avoided a proxy fight with Carl Icahn and associates, the biotech's next step likely will be to consider the damage left by a year's worth of manufacturing woes and the problems that resulted, including shortages of its top-selling products, the launch of new competition to those drugs, and an FDA consent decree governing operations at its Allston Landing, Mass., plant
You may also be interested in...
In exchange for withdrawing its proxy slate and agreeing to back Genzyme's nominees, Icahn Partners get two seats on biotech's board.
Unveiling its first-quarter financial results, Genzyme reports significant year-over-year sales decreases for Cerezyme and Fabrazyme.
Despite agreeing to support Biogen's nominee slate, Icahn says he still will push for biotech sale.